Ces radiol. 2017, 71(1):65-69 | DOI: 10.55095/CesRadiol2017/006

18F-FDG PET/CT imaging of the disseminated malignant schwannomaCase report

Jiří Doležal1, Dagmar Kalousová2, Eva Krčálová1, Karel Pokorný3, Kateřina Vondráčková4
1 Oddělení nukleární medicíny LF UK a FN, Hradec Králové
2 Radiologická klinika LF UK a FN, Hradec Králové
3 Klinika otorinolaryngologie a chirurgie hlavy a krku, Pardubická nemocnice, Pardubice
4 Onkologické a radiologické centrum Pardubice, Multiscan, Pardubice

Aim: To present a rare case report about 45-year-old man with disseminated malignant schwannoma nervus facialis which was detected by means of 18F-FDG PET/CT imaging.

Method: The patient was examined for growing the right retroauricular mass. The resection of the mass was performed and malignant schwannoma was proven. The staging PET/CT scan was obtained 60 minutes after intravenous injection of 18F-FDG. The PET scan acquisition time was 2.5 minutes per bed position and nine bed positions were necessary. Contrast-enhanced CT (venous phase) provided both full CT evaluation (including intravenous and oral contrast) and PET attenuation correction.

Results: The PET/CT demonstrated focal the 18F-FDG uptake in the residual tumor on the right side of the neck near the processus mastoideus. The patient underwent the subtotal resection of the right temporal bone with the right parotidectomy and the right lymph nodes neck dissection and subsequently adjuvant chemotherapy. The re-staging PET/CT showed the malignant schwannoma dissemination to lungs, right neck, hilar and subcarinal lymph nodes, muscles, the second cervical vertebra and peritoneum. The palliative chemotherapy was given.

Conclusion: In this report the staging, respectively re-staging 18F-FDG PET/CT imaging correctly detected residual malignant schwannoma nervus facialis, respectively dissemination after treatment. The PET/CT imaging improved the patient management and the finding resulted in treatment changes.

Keywords: malignant schwannoma, positron emission tomography, fluorodeoxyglucose
Grants and funding:

Podpořeno MZ ČR - RVO (FNHK, 00179906).

Accepted: February 12, 2017; Published: March 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Doležal J, Kalousová D, Krčálová E, Pokorný K, Vondráčková K. 18F-FDG PET/CT imaging of the disseminated malignant schwannoma. Ces radiol. 2017;71(1):65-69. doi: 10.55095/CesRadiol2017/006.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dominguez J, Lobato RD, Ramos A, Rival JJ, Gomez PA, Astro S. Giant intrasacral schwannomas: Report of six cases. Acta Neurochir (Wien) 1997; 139(10): 954-960. Go to original source... Go to PubMed...
    2. Choudry HA, Nikfarjam M, Liang JJ, Kimchi ET, Conter R, Gusami NJ, Staveley-O'Caroll KF. Diagnosis and management of retroperitoneal ancienit schwannomas. World J Surg Oncol 2009; 7: 12; doi:10.1186/1477-7819-7-12 Go to original source... Go to PubMed...
    3. Li Q, Gao C, Juzi JT, Hao X. Analysis of 82 cases of retroperitoneal schwannoma. ANZ J Surg 2007; 77(4): 237-240. Go to original source... Go to PubMed...
    4. Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, Lozza L, Collini P, Olmi P, Casali PG, Pilotti S, Gronchi A. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer 2006; 107(5): 1065-1074. Go to original source... Go to PubMed...
    5. Stark AM, Buhl R, Hugo HH, Mehdom HM. Malignant peripheral nerve sheath tumors - report of 8 cases and review of the literature. Acta Neurochir (Wien) 2001; 143(4): 357-364. Go to original source... Go to PubMed...
    6. Benz MR, Tchekmedyian N, Eilber FC, Federman N, Czernin J, Tap WD. Utilization of positron emission tomography in the management of patients with sarcoma. Curr Opin Oncol 2009; 21(4): 345-351. Go to original source... Go to PubMed...
    7. Ziessman HA, O'Malley J, Thrall JH. Nuclear medicine - the requisites in radiology, third edition. Philadelphia: Elsevier Mosby 2006; 302-305.
    8. Xu H, Sha N, Li HW, Bai M, Chen X, Hu HL, Wu ChL. A giant pelvic malignant schwannoma: a case report and literature review. Int J Clin Exp Pathol 2015; 8(11): 15363-15368.
    9. Mishra B, Madhusudham KS, Kilambi R, Das P, Pal S, Srivastava DN. Malignant Schwannoma of the Esophagus: a rare case report. Korean J Thorac Cardiovasc Surg 2016; 49(1): 63-66. Go to original source... Go to PubMed...
    10. Halac M, Cnaral F, Sait S, Ylmaz S, Kerin S, Sergülen D, Uslu I. FDG PET/CT findings in recurrent malignant schwannoma. Clin Nucl Med 2008; 33(3): 172-174. Go to original source... Go to PubMed...
    11. Evangelista L, Burei M, Basso U. A solitary metastasis for a malignant schwannoma in the Gallbladder detected by 18F-FDG PET/CT. Clin Nucl Med 2016; 41(8): 666-667. Go to original source... Go to PubMed...
    12. Khiewvan B, Macapinlac HA, Lev D, McCutcheon IE, Slopis JM, Al Sannaa G, Wei W, Chuang HH. The value of 18F-FDG PET/CT in the management of malignat peripheral nerve sheath tumors. Eur J Nucl Med Mol Imaging 2014; 41(9): 1756-1766. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content